CN113453691A - 芍药内酯苷在制备快速治疗抑郁症的药物中的用途 - Google Patents

芍药内酯苷在制备快速治疗抑郁症的药物中的用途 Download PDF

Info

Publication number
CN113453691A
CN113453691A CN201980092499.4A CN201980092499A CN113453691A CN 113453691 A CN113453691 A CN 113453691A CN 201980092499 A CN201980092499 A CN 201980092499A CN 113453691 A CN113453691 A CN 113453691A
Authority
CN
China
Prior art keywords
albiflorin
nmda receptor
pharmaceutically acceptable
acceptable salt
antidepressant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980092499.4A
Other languages
English (en)
Inventor
张作光
田晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN113453691A publication Critical patent/CN113453691A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

提供了芍药内酯苷或其药学上可接受的盐、或者包含芍药内酯苷或其药学上可接受的盐的提取物在制备用于通过抑制NMDA受体快速治疗抑郁症的药物、食品、保健品、食品添加剂或营养补充剂中的用途；还提供了芍药内酯苷或其药学上可接受的盐、或者包含芍药内酯苷或其药学上可接受的盐的提取物在制备NMDA受体抑制剂中的用途。此外，还提供了一种通过抑制NMDA受体快速治疗抑郁症的方法。与氯胺酮等类型的速效抗抑郁在研药物相比，NMDA受体抑制剂芍药内酯苷和其药学上可接受的盐更为安全，不存在诸如解离和出现幻觉等精神方面副作用，也不存在成瘾性的隐患。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN201980092499.4A 2019-02-21 2019-11-15 芍药内酯苷在制备快速治疗抑郁症的药物中的用途 Pending CN113453691A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019101241309 2019-02-21
CN201910124130 2019-02-21
PCT/CN2019/118751 WO2020168760A1 (zh) 2019-02-21 2019-11-15 芍药内酯苷在制备快速治疗抑郁症的药物中的用途

Publications (1)

Publication Number Publication Date
CN113453691A true CN113453691A (zh) 2021-09-28

Family

ID=72144052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980092499.4A Pending CN113453691A (zh) 2019-02-21 2019-11-15 芍药内酯苷在制备快速治疗抑郁症的药物中的用途

Country Status (2)

Country Link
CN (1) CN113453691A (zh)
WO (1) WO2020168760A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038610A2 (en) * 2005-09-26 2007-04-05 President & Fellows Of Harvard College Use of natural products for treatment of neurological disorders
CN101940583A (zh) * 2009-07-10 2011-01-12 张作光 芍药苷与芍药内酯苷组合物的抗抑郁用途及其制备方法
CN102038701A (zh) * 2009-10-20 2011-05-04 张作光 芍药内酯苷的抗抑郁用途
CN107397752A (zh) * 2016-10-11 2017-11-28 张作光 芍药内酯苷在制备改善肠道菌群系统功能的产品中的用途
CN107412244A (zh) * 2016-10-11 2017-12-01 张作光 芍药内酯苷在制备改善褪黑素系统功能的产品中的用途
CN107496434A (zh) * 2017-01-06 2017-12-22 张作光 芍药内酯苷作为吲哚胺2,3‑双加氧酶（ido）抑制剂的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102125575A (zh) * 2010-01-19 2011-07-20 张作光 芍药内酯苷的抗帕金森症用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038610A2 (en) * 2005-09-26 2007-04-05 President & Fellows Of Harvard College Use of natural products for treatment of neurological disorders
CN101940583A (zh) * 2009-07-10 2011-01-12 张作光 芍药苷与芍药内酯苷组合物的抗抑郁用途及其制备方法
CN102038701A (zh) * 2009-10-20 2011-05-04 张作光 芍药内酯苷的抗抑郁用途
CN107397752A (zh) * 2016-10-11 2017-11-28 张作光 芍药内酯苷在制备改善肠道菌群系统功能的产品中的用途
CN107412244A (zh) * 2016-10-11 2017-12-01 张作光 芍药内酯苷在制备改善褪黑素系统功能的产品中的用途
CN107496434A (zh) * 2017-01-06 2017-12-22 张作光 芍药内酯苷作为吲哚胺2,3‑双加氧酶（ido）抑制剂的用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JINGJING SONG等: "Not only serotonergic system, but also dopaminergic system involved in albiflorin against chronic unpredictable mild stress-induced depression-like behavior in rats", 《CHEMICO-BIOLOGICAL INTERACTIONS》 *
YU-LU WANG等: "Antidepressant-like effects of albiflorin extracted from Radix paeoniae Alba", 《JOURNAL OFETHNOPHARMACOLOGY》 *
包祖晓主编: "《抑郁症诊治心悟》", 31 January 2014, 人民军医出版社 *
张建军等: "芍药内酯苷抗抑郁作用的实验研究", 《中药与临床》 *
郑永唐等主编: "《树鼩基础生物学与疾病模型》", 30 November 2014, 云南科学技术出版社 *
阮迪云主编: "《神经生物学》", 31 October 2008, 中国科学技术大学出版社 *

Also Published As

Publication number Publication date
WO2020168760A1 (zh) 2020-08-27

Similar Documents

Publication Publication Date Title
US8148354B2 (en) Use of 20(S)-protopanaxadiol in manufacture of antidepressants
US10238676B2 (en) Application of ginsenoside RG3 in preparing medicine for preventing and/or treating dementia, and medicine for treating dementia
NO338015B1 (no) Farmasøytisk sammensetning for anvendelse i behandling av depresjon og fremgangsmåte for fremstilling derav
WO2016107540A1 (zh) 一种预防或治疗心脑血管疾病或痴呆症的中药组合物及其制备方法和用途
WO2008000142A1 (fr) Agoniste du transporteur de la dopamine et ses utilisations
BR112017005416B1 (pt) composição farmacológica para uso em medicamento para tratar ou prevenir doenças neurológicas degenerativas contendo como ingrediente ativo extrato de mistura de casca da raiz de peônia da montanha, raiz de angelica dahurica e raiz de bupleurum ou fragmentos dos mesmos
He et al. Absorption properties of luteolin and apigenin in Genkwa Flos using in situ single-pass intestinal perfusion system in the rat
US20130316966A1 (en) Use of albiflorin and metabolites thereof
CN112933073A (zh) L-4-氯犬尿氨酸的剂型和治疗用途
WO2018126673A1 (zh) 芍药内酯苷作为吲哚胺2,3-双加氧酶(ido)抑制剂的用途
CN102743401A (zh) 人参二醇皂苷组分在制备防治癫痫药物中的用途
CN114209739A (zh) 一种白头翁提取物在制备治疗抗抑郁药物上的应用
Wang et al. Network pharmacology and pharmacological evaluation for deciphering novel indication of Sishen Wan in insomnia treatment
Chen et al. Component identification of modified sanmiao pills by UPLC-Xevo G2-XS QTOF and its anti-gouty arthritis mechanism based on network pharmacology and experimental verification
Lee et al. Wild ginseng attenuates repeated morphine-induced behavioral sensitization in rats
CN114832006B (zh) 人参皂苷Rh4在制备用于抑制睡眠的药物中的用途
CN113453691A (zh) 芍药内酯苷在制备快速治疗抑郁症的药物中的用途
Macêdo et al. Lippia origanoides essential oil induces tocolytic effect in virgin rat uterus and inhibits writhing in a dysmenorrhea mouse model
CN116019819A (zh) 一种活性人参皂苷组合物及其制备方法和应用
WO2009062374A1 (fr) Utilisation pharmaceutique de liquiritigénine pour préparer un médicament destiné au traitement de maladies neurodégénératives
JP7465337B2 (ja) リモノイド化合物およびｓｇｌｔ－２阻害剤を含有する組合せ製品
WO2021027582A1 (zh) 包含柠檬苦素类化合物和噻唑烷二酮类药物的组合产品
CN112691102A (zh) 黄芩素在防治帕金森病/帕金森综合征抑郁症状中的应用
Marzo et al. Pharmacokinetics of isoxsuprine hydrochloride administered orally and intramuscularly to female healthy volunteers
Wang et al. Cytisine: state of the art in pharmacological activities and pharmacokinetics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210928